Ahmed M. Elkhanany

Ahmed M. Elkhanany

Hematology Oncology | Oncology | Medical Genetics
7200 Cambridge St
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Corrigendum to "NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis" [Cancer Lett. 655 (2026) 218636].

Corrigendum to "NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis" [Cancer Lett. 655 (2026) 218636].

Journal: Cancer letters
Published: August 16, 2026

Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study.

Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study.

Journal: JCO precision oncology
Published: June 24, 2026

NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis.

NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis.

Journal: Cancer letters
Published: March 24, 2026

AADAT-Driven Metabolic Control of Malate and CoQ 10 Shapes Immune Evasion in Triple-Negative Breast Cancer.

AADAT-Driven Metabolic Control of Malate and CoQ 10 Shapes Immune Evasion in Triple-Negative Breast Cancer.

Journal: bioRxiv : the preprint server for biology
Published: February 09, 2026

CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials.

CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials.

Journal: The Lancet. Oncology
Published: November 07, 2025

CDK4/6 Inhibitors in Breast Cancer-Who Should Receive Them?

CDK4/6 Inhibitors in Breast Cancer-Who Should Receive Them?

Journal: International journal of molecular sciences
Published: September 24, 2025

Therapeutic Clinical Trial Eligibility and Enrollment among Women with Breast Cancer: Implications for Understanding Trial Disparities.

Therapeutic Clinical Trial Eligibility and Enrollment among Women with Breast Cancer: Implications for Understanding Trial Disparities.

Journal: Annals of surgical oncology
Published: September 09, 2024

Increasing inclusion and equity for Black women in breast cancer clinical trials.

Increasing inclusion and equity for Black women in breast cancer clinical trials.

Journal: Clinical advances in hematology & oncology : H&O
Published: May 13, 2024

Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model.

Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model.

Journal: JCO clinical cancer informatics
Published: June 23, 2023

Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.

Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 25, 2023

Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma.

Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma.

Journal: Cancers
Published: March 23, 2023

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.

Journal: Breast cancer research and treatment
Published: October 17, 2022
Showing 1-12 of 24

Last Updated: 09/26/2026